(Q37683962)

22 August 2017

1 reference

title

Serogroup B meningococcal vaccines-an unfinished story (English)

1 reference

22 August 2017

Manish Sadarangani

1

0 references

Andrew Pollard

series ordinal

2

object named as

Andrew J Pollard

1 reference

22 August 2017

1 February 2010

1 reference

Lancet Infectious Diseases

22 August 2017

1 reference

22 August 2017

10

1 reference

22 August 2017

2

1 reference

22 August 2017

112-124

1 reference

Ascertainment of meningococcal disease in Europe

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Epidemiology of meningococcal disease in southern Brazil from 1995 to 2003, and molecular characterization of Neisseria meningitidis using multilocus sequence typing

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Human immunity to the meningococcus. I. The role of humoral antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Meningococcal surrogates of protection--serum bactericidal antibody activity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Disease susceptibility to ST11 complex meningococci bearing serogroup C or W135 polysaccharide capsules, North America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Immunologic response of man to group B meningococcal polysaccharide vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Complex of Meningococcal Group B Polysaccharide and Type 2 Outer Membrane Protein Immunogenic in Man

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Immunogenicity in adult males of a Neisseria meningitidis group B vaccine composed of polysaccharide complexed with outer membrane proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Antibody response of adults to an aluminum hydroxide-adsorbed Neisseria meningitidis serotype 2b protein-group B polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Classification of Neisseria meningitidis Group B into Distinct Serotypes. III. Application of a New Bactericidal-Inhibition Technique to Distribution of Serotypes among Cases and Carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Development of Antibodies to Meningococcal Protein and Lipopolysaccharide Serotype Antigens in Healthy Carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Safety and immunogenicity of a Neisseria meningitidis type 2 protein vaccine in animals and humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

The epidemiological impact of antimeningococcal B vaccination in Cuba

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Prolonged outbreak of B meningococcal disease in the Seine-Maritime department, France, January 2003 to June 2005.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

A prospective study of the effectiveness of the New Zealand meningococcal B vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

RE: "A PROSPECTIVE STUDY OF THE EFFECTIVENESS OF THE NEW ZEALAND MENINGOCOCCAL B VACCINE"

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

A universal vaccine for serogroup B meningococcus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Meningococcal genetic variation mechanisms viewed through comparative analysis of serogroup C strain FAM18.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Complete Genome Sequence of Neisseria meningitidis Serogroup B Strain MC58

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Vaccine potential of the Neisseria meningitidis 2086 lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor h-binding protein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Solution structure of the immunodominant domain of protective antigen GNA1870 of Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Solution Structure of the Factor H-binding Protein, a Survival Factor and Protective Antigen of Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Epitope mapping of a bactericidal monoclonal antibody against the factor H binding protein of Neisseria meningitidis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Human monocytes/macrophages are a target of Neisseria meningitidis Adhesin A (NadA).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Candidate Neisseria meningitidis NspA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Evaluation of recombinant transferrin-binding protein B variants from Neisseria meningitidis for their ability to induce cross-reactive and bactericidal antibodies against a genetically diverse collection of serogroup B strains

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

The meningococcal transferrin-binding proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Vaccine potential of the Neisseria meningitidis lactoferrin-binding proteins LbpA and LbpB

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Vaccine potential of meningococcal FrpB: studies on surface exposure and functional attributes of common epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Identification of new meningococcal serogroup B surface antigens through a systematic analysis of neisserial genomes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Peptide mimics of the group B meningococcal capsule induce bactericidal and protective antibodies after immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Antiidiotypic DNA vaccination induces serum bactericidal activity and protection against group B meningococci

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Conjugation of meningococcal lipopolysaccharide R-type oligosaccharides to tetanus toxoid as route to a potential vaccine against group B Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: developmental chemistry and investigation of immunological responses following immunization of mice and rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Infection with an avirulent phoP mutant of Neisseria meningitidis confers broad cross-reactive immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live Meningococci

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Identification by genomic immunization of a pool of DNA vaccine candidates that confer protective immunity in mice against Neisseria meningitidis serogroup B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Human immunity to the meningococcus. II. Development of natural immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Differential activation of human and mouse Toll-like receptor 4 by the adjuvant candidate LpxL1 of Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Meningococcal C conjugate vaccine: the experience in England and Wales

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

Assessing the economics of vaccination for Neisseria meningitidis in industrialized nations: a review and recommendations for further research

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970324-X

7 January 2021

10.1016/S1473-3099(09)70324-X

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20113980